

Performance-powered. The OneTouch® Ping® insulin pump and meter-remote.

NOT ALL
INSULIN DELIVERY IS
CREATED
EQUAL

We don't just deliver insulin.



We deliver outstanding
clinical performance.



Johnson & Johnson DIABETES SOLUTIONS COMPANIES



OneTouch® Ping®. Where clinical performance meets lifestyle performance.

5 big advantages of pump therapy compared with multiple daily injections.

- 1 Lower HbA1c levels¹⁴
- 2 Reduced glycemic variability^{3,5}
- 3 Reduced severe hypoglycemia^{2,4,6,7}
- 4 Fewer daily injections
- 5 More flexibility

The majority of people who change to an insulin pump don't go back to injections.¹



8 big advantages of OneTouch® Ping®.

OneTouch® Ultra® Blue Test Strips have DoubleSure™ Technology, which automatically checks each blood sample twice to confirm the result

Superior bolus calculator* at achieving postprandial control vs. the Medtronic Bolus Wizard^{®§}

Significantly better accuracy per basal delivery vs. Medtronic,[†] Roche, and Next-Generation OmniPod[®] in a study comparing dose-to-dose variability[‡]

Fine-tuned control with the only insulin pump to deliver basal insulin in 0.025 U/hr increments across all available rates (0.025 U/hr–25 U/hr)

Discreet diabetes management with remote bolus

Accurate carb counting via built-in CalorieKing™ food database

Outstanding readability for patients with low vision[¶]

Uninterrupted insulin delivery with waterproof pump[§]

*Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas® 2020, MiniMed Paradigm®, and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas® 2020 bolus calculator algorithm is identical to the OneTouch® Ping® calculator. The bolus calculator in the Medtronic MiniMed® 530G pump is unchanged from the bolus calculator in the Paradigm® Revel™ pump.
 †The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences.
 ‡Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. *J Diabetes Sci Technol.* 2013;7(4):1011-1020. (Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo®, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy comparison between Animas OneTouch® Ping®, Insulet OmniPod®, and Next-Generation OmniPod®. Abstract and poster presented at: Diabetes Technology Society Meeting; October 31–November 2, 2013; San Francisco, CA.
 §The OneTouch® Ping® insulin pump is tested and proven waterproof at 12 feet for 24 hours. The meter-remote must not be exposed to water.


Not all bolus calculators are created equal.^{8*}

Our bolus calculator is superior at achieving postprandial control versus the Medtronic Bolus Wizard.^{8†}

The MiniMed[®] 530G bolus calculator is unchanged from the Paradigm[®] Revel[™] bolus calculator.

In a clinical study, the automated bolus calculator used in OneTouch[®] Ping[®] was shown to be more efficacious in controlling postprandial hyperglycemia than the Medtronic Bolus Wizard[®].^{8*} The postprandial target range for this study was set at 80 mg/dL to 140 mg/dL.


PROXIMITY TO TARGET 6 HOURS POST-MEAL



The automated bolus calculator used in OneTouch[®] Ping[®] recommended a correction insulin bolus significantly more frequently than the Medtronic Bolus Wizard[®] (P=.0002).^{8*}

TIME WITHIN TARGET BLOOD GLUCOSE RANGE

(44-hour study interval)



Automated bolus calculator technology that excels.
The bolus calculator in OneTouch[®] Ping[®] corrects to the midpoint of the programmed target blood glucose range. The Medtronic Bolus Wizard[®] corrects to the outer limits of the target. This can impact the amount of insulin recommended and whether or not a correction is recommended.^{8†}

^{8*}Twenty-four patients with type 1 diabetes used the bolus calculators from the Animas[®] 2020, MiniMed Paradigm[®], and Roche Combo insulin pump systems to correct postprandial hyperglycemia. The Animas[®] 2020 bolus calculator algorithm is identical to the OneTouch[®] Ping[®] calculator. The bolus calculator in the Medtronic MiniMed[®] 530G pump is unchanged from the bolus calculator in the Paradigm[®] Revel[™] pump.
[†]Medtronic Bolus Wizard[®] feature information from Medtronic MiniMed Paradigm[®] Revel[™] and 530G User Guides and Zisser H, Wagner R, Pleus S, et al. *Diabetes Technol Ther*. 2010;12(12):955-961.

Not all basal insulin delivery is created equal.*

OneTouch® Ping® demonstrates superior accuracy per delivery of basal insulin versus Medtronic,† Roche, and Next-Generation OmniPod®.*

The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences.


OneTouch® Ping® was proven superior in accuracy in a study comparing dose-to-dose variability by pump versus Medtronic,‡ Roche, and Next-Generation OmniPod®.

All pumps in the study were programmed to deliver a basal rate of 0.5 U/hr over 20 hours, with the Next-Generation OmniPod® delivering 0.05 U basal doses every 6 minutes while the other three pumps delivered 0.025 U basal doses every 3 minutes.


Thirty data sets were assessed. In total, 5,977 doses, 12,000 doses, 11,987 doses, and 11,947 doses were delivered for Next-Generation OmniPod®, OneTouch® Ping®, Medtronic,‡ and Roche pumps, respectively.

DOSE-TO-DOSE VARIABILITY COMPARISON OF TYPICAL PUMP® PERFORMANCE


OneTouch® Ping® vs. Medtronic†



OneTouch® Ping® vs. Roche



OneTouch® Ping® vs. Next-Generation OmniPod®



CUMULATIVE DOSES WITHIN ±10% ACCURACY THRESHOLD FOR ALL 30 DATA SETS

86% OneTouch® Ping®
73% Medtronic†
P = .0009

86% OneTouch® Ping®
76% Roche
P = .0019

86% OneTouch® Ping®
23% Next-Generation OmniPod®
P < .0001

More accurate basal delivery versus Medtronic, Roche, and Next-Generation OmniPod®.

In a study comparing the dose-to-dose variability of the OneTouch® Ping® versus Medtronic, Roche, and Next-Generation OmniPod®, OneTouch® Ping® was proven to deliver fewer doses that deviated from the target volume.*

*Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. *J Diabetes Sci Technol*. 2013;7(4):1011-1020. (Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Vevo®, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy comparison between Animas OneTouch® Ping®, Insulet OmniPod®, and Next-Generation OmniPod®. Abstract and poster presented at: Diabetes Technology Society Meeting; October 31-November 2, 2013; San Francisco, CA.

†A combination of two Medtronic MiniMed Paradigm® Revel™ and four Vevo® pumps were assessed. The Paradigm® Vevo® pump is available for sale in select markets outside the U.S.

‡The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences.

§For each manufacturer, the "typical pump" is the data set with the median standard deviation in dose percent error.

OneTouch® Ping®

Where clinical performance meets lifestyle performance.

- > Superior at reducing postprandial hyperglycemia vs. Medtronic^{**}
- > More accurate basal delivery vs. Medtronic, Roche, and Next-Generation OmniPod[†]
- > Discreet diabetes management, outstanding readability, and carb counting accuracy
- > Uninterrupted insulin delivery with a pump that is proven waterproof at 12 feet for 24 hours[‡]

*The Medtronic MiniMed® 530G pump is unchanged from the Paradigm® Revel™ pump with the exception of the added Threshold Suspend tool, and some minor software differences.

†Bench data: Jahn LG, Capurro JJ, Levy BL. Comparative dose accuracy of durable and patch insulin infusion pumps. *J Diabetes Sci Technol*. 2013;7(4):1011-1020. (Study conducted using OneTouch® Ping® versus other leading pumps, including Medtronic MiniMed Paradigm® Revel™/Veo™, Roche ACCU-CHEK® Combo, and Insulet OmniPod®.) Capurro J, Levy B. Dose accuracy comparison between Animas OneTouch® Ping®, Insulet OmniPod®, and Next-Generation OmniPod®. Abstract and poster presented at: Diabetes Technology Society Meeting; October 31-November 2, 2013; San Francisco, CA.

‡The meter-remote must not be exposed to water.



Animas has received both ISO 13485:2003 (International Organization for Standardization) certification and The Joint Commission accreditation. By meeting these most rigorous standards, Animas is committed to superior quality and safety for its customers.

Animas Corporation
A Johnson & Johnson Company
200 Lawrence Drive
West Chester, PA 19380
Phone: 1-877-YES-PUMP (1-877-937-7867)
Email: comments@animas.com
www.animas.com

Johnson & Johnson DIABETES SOLUTIONS COMPANIES



1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. *Diabetes Care*. 2003;26(4):1079-1087. 2. Rudolph JW, Hirsch IB. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. *Endocr Pract*. 2002;8(6):401-405. 3. Hoogma RPLM, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycemic control and quality of life: results of the 5-nations trial. *Diabet Med*. 2005;23(2):141-147. 4. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. *Diabet Med*. 2002;19(9):746-751. 5. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. *BMJ*. 2002;324(7739):705+. 6. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. *Diabetes Care*. 1996;19(4):324-327. 7. Bode BW, Sabbah HT, Gross TM, Frederickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. *Diabetes Metab Res Rev*. 2002;18(suppl 1):S14-S20. 8. Zisser H, Wagner R, Pleus S, et al. Clinical performance of three bolus calculators in subjects with type 1 diabetes mellitus: a head-to-head comparison. *Diabetes Technol Ther*. 2010;12(12):955-961. 9. Burton DM, Usilan MM, Blubaugh MV, Clements CW 3rd. Are current insulin pumps accessible to blind and visually impaired people? *J Diabetes Sci Technol*. 2009;3(3):613-618.

All product names and trademarks are the property of their respective owners.
© 2013 Animas Corporation 2013/3 Rx Only. DCF-13-2287B
© 2013 LifeScan, Inc. Milpitas, CA 95035 10/13